Aggregated price index with volume information
Summary:
- Gene Therapy stocks down 2.1% on average while median return down 1.0% in a day
- Gene Therapy stocks down 11.2% on average while median return down 12.9% in a week
- Gene Therapy stocks up 24.2% on average while median return up -21.1% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $ADVM 574.8%, $BMRN 5.6%
- 1M losers are : Losers for past month are $CAPR -25.6%, $RGNX -28.2%, $EDIT -28.3%, $BLUE -31.6%, $SLDB -37.4%
- 1W winners are : Winners for past week are
- 1W losers are : Losers for past week are $NTLA -14.8%, $RGNX -15.5%, $EDIT -15.5%, $BLUE -17.4%, $CAPR -18.9%
Correlation Analysis
Index correlation analysis
Correlation for the past month is 19.1%, for the past 3 months is 24.8%
In the past month for a 5 days rolling window, the highest corrrelation is 48.4%, the lowest correlation is 0.2%, the latest correlation is 0.2%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 83.3% between EDIT and NTLA
The lowest correlation is -50.6% between EDIT and ORTX
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL. The details of the oral presentation are below: Session: Oral Abstract Session IPresentation ID #196Title: Results of a Phase 1, Open-label, Dos
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Key Insights Significantly high institutional ownership implies REGENXBIO's stock price is sensitive to their trading...
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $57.96, marking a -1.29% move from the previous day.
Ultragenyx (RARE) reports positive interim data from the phase I/II study of GTX-102 for Angelman syndrome. However, the stock declines due to safety concerns.
This small biotech is struggling to fly -- and investors should probably steer clear.
It might be of some concern to shareholders to see the CRISPR Therapeutics AG ( NASDAQ:CRSP ) share price down 17% in...
Treatment appeared to result in functional and cognitive gains in people with the neurological disorder. Three participants experienced lower extremity weakness, however.